Indivior (INDV) Expected to Release Quarterly Earnings on Thursday

Indivior (NASDAQ:INDV) is expected to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Indivior to announce earnings of $1.06 per share and revenue of $329.35 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.

Indivior (NASDAQ:INDV) last released its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The company had revenue of $343.00 million during the quarter. On average, analysts expect Indivior to post $3.66 EPS for the current fiscal year and $3.83 EPS for the next fiscal year.

Indivior Stock Performance

Shares of Indivior stock opened at $34.72 on Wednesday. Indivior has a 12-month low of $24.28 and a 12-month high of $42.81. The firm’s 50 day simple moving average is $35.41 and its two-hundred day simple moving average is $35.62.

Indivior Announces Dividend

The company also recently disclosed a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be issued a $8.13 dividend.

Insider Transactions at Indivior

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of Indivior stock in a transaction dated Thursday, August 27th. The shares were acquired at an average cost of $35.69 per share, with a total value of $53,535.00. Following the purchase, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. The trade was a 5.74% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on INDV shares. Barclays cut their price target on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Finally, Craig Hallum reiterated a “buy” rating and issued a $53.00 target price on shares of Indivior in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $45.17.

Indivior Company Profile

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.